Eisai Seeks Traditional Approval With New Lecanemab Data Und

The FDA has accepted for Priority Review the sBLA for Leqembi (lecanemab-irmb) to convert its accelerated approval status to a traditional approval.

Related Keywords

, Drug Administration , Priority Review , Biologics License Application , Clinical Dementia Rating Sum , Scale Cognitive Subscale , Prescription Drug User Fee Act ,